[go: up one dir, main page]

PL2726600T3 - Hodowla ssaczych komórek - Google Patents

Hodowla ssaczych komórek

Info

Publication number
PL2726600T3
PL2726600T3 PL12738674T PL12738674T PL2726600T3 PL 2726600 T3 PL2726600 T3 PL 2726600T3 PL 12738674 T PL12738674 T PL 12738674T PL 12738674 T PL12738674 T PL 12738674T PL 2726600 T3 PL2726600 T3 PL 2726600T3
Authority
PL
Poland
Prior art keywords
culture
mammalian cells
mammalian
cells
Prior art date
Application number
PL12738674T
Other languages
English (en)
Inventor
Brian D. Follstad
Rebecca E. Mccoy
Arvia E. Morris
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46579326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2726600(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of PL2726600T3 publication Critical patent/PL2726600T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/10—Perfusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL12738674T 2011-07-01 2012-06-29 Hodowla ssaczych komórek PL2726600T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161503737P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
PL2726600T3 true PL2726600T3 (pl) 2017-08-31

Family

ID=46579326

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14187232T PL2837680T3 (pl) 2011-07-01 2012-06-29 Hodowla ssaczych komórek
PL12738674T PL2726600T3 (pl) 2011-07-01 2012-06-29 Hodowla ssaczych komórek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14187232T PL2837680T3 (pl) 2011-07-01 2012-06-29 Hodowla ssaczych komórek

Country Status (24)

Country Link
US (7) US11292829B2 (pl)
EP (2) EP2837680B1 (pl)
JP (1) JP5897708B2 (pl)
KR (8) KR102108663B1 (pl)
CN (2) CN103827292B (pl)
AU (5) AU2012279230B2 (pl)
BR (2) BR122021007265B1 (pl)
CA (2) CA2838695C (pl)
CL (2) CL2013003792A1 (pl)
CY (2) CY1118863T1 (pl)
DK (2) DK2726600T3 (pl)
EA (1) EA039023B1 (pl)
ES (2) ES2625045T3 (pl)
HK (2) HK1197081A1 (pl)
HU (2) HUE033279T2 (pl)
IL (6) IL288509B2 (pl)
LT (2) LT2837680T (pl)
MX (2) MX387489B (pl)
PL (2) PL2837680T3 (pl)
PT (2) PT2726600T (pl)
SG (1) SG10201702537RA (pl)
SI (2) SI2726600T1 (pl)
WO (1) WO2013006479A2 (pl)
ZA (1) ZA201309372B (pl)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
MX345141B (es) 2006-09-13 2017-01-18 Abbvie Inc * Mejoras de cultivos celulares.
WO2010141039A1 (en) 2008-10-20 2010-12-09 Abbott Laboratories Isolation and purification of antibodies using protein a affinity chromatography
CN102257005A (zh) 2008-10-20 2011-11-23 雅培制药有限公司 在抗体纯化过程中的病毒灭活
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
SG10201702537RA (en) * 2011-07-01 2017-04-27 Amgen Inc Mammalian cell culture
ES2734070T3 (es) 2011-10-18 2019-12-04 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con iones de magnesio
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2014011629A1 (en) 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Stable aqueous formulations of etanercept
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
CN104902914B (zh) 2012-09-11 2019-01-01 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
WO2014109858A1 (en) * 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
TWI832345B (zh) * 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
KR20150133833A (ko) * 2013-03-26 2015-11-30 코히러스 바이오사이언시즈, 인코포레이티드 단백질 생산 방법
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US11130980B2 (en) * 2013-10-31 2021-09-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP2017500017A (ja) * 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
BR122020004385B1 (pt) 2014-01-13 2022-10-04 Amgen Inc Método para aumentar o teor de glicoforma de alta manose de uma glicoproteína recombinante e método de produção de uma glicoproteína recombinante
US10047141B2 (en) 2014-01-30 2018-08-14 Coherus Biosciences, Inc. Method of manufacturing a protein by perfusion in media with a low amino acid concentration
PL4219687T3 (pl) 2014-04-23 2024-10-28 Juno Therapeutics, Inc. Metody izolacji, hodowli i inżynierii genetycznej populacji komórek odpornościowych na potrzeby terapii adopcyjnej
ES2909630T3 (es) 2014-06-04 2022-05-09 Amgen Inc Métodos de recolección en cultivos de células de mamífero
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
TWI776235B (zh) * 2014-06-09 2022-09-01 美商健臻公司 種子罐培養法(seed train processes)及其用途
JP6530171B2 (ja) * 2014-09-09 2019-06-12 旭化成メディカル株式会社 培養産生物の回収方法
AU2015355087B2 (en) * 2014-12-01 2020-04-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105385731B (zh) * 2015-12-25 2018-10-30 上海莱士血液制品股份有限公司 一种表达重组八因子的灌注培养方法
JP2019500878A (ja) * 2016-01-06 2019-01-17 オンコバイオロジクス，インコーポレイティド モノクローナル抗体組成物中の高分子量種、酸性荷電種、及び断片の低減
AU2017213775A1 (en) 2016-02-03 2018-08-16 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US11377677B2 (en) 2016-03-02 2022-07-05 Lonza Ltd Fermentation process
EP3601584A1 (en) * 2017-03-31 2020-02-05 Boehringer Ingelheim International GmbH Perfusion medium
EP3601586A1 (en) * 2017-03-31 2020-02-05 Boehringer Ingelheim International GmbH Perfusion medium
WO2018229802A1 (en) * 2017-06-16 2018-12-20 Ge Healthcare Bio-Sciences Ab Method for predicting outcome of and modelling of a process in a bioreactor
BR112020001605A2 (pt) 2017-08-09 2020-08-11 Juno Therapeutics Inc métodos para produzir composições de células geneticamente modificadas e composições relacionadas
JP7323512B2 (ja) 2017-10-06 2023-08-08 ロンザ リミテッド ラマン分光法を使用する細胞培養の自動制御
TW202426623A (zh) 2017-10-16 2024-07-01 美商再生元醫藥公司 灌注生物反應器及相關使用方法
CN111542596B (zh) 2017-11-01 2025-01-14 朱诺治疗学股份有限公司 产生工程化细胞的治疗性组合物的方法
EP3720874A1 (en) * 2017-12-08 2020-10-14 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
EP3788076A1 (en) 2018-05-01 2021-03-10 Amgen Inc. Antibodies with modulated glycan profiles
AU2019299358A1 (en) * 2018-07-03 2021-02-18 Bristol-Myers Squibb Company Methods of producing recombinant proteins
CA3122774A1 (en) * 2018-12-31 2020-07-09 Repligen Corporation Filter for mammalian cell culture perfusion and clarification with hydrophobic hollow fiber
US20220340948A1 (en) * 2019-09-27 2022-10-27 Boehringer Ingelheim International Gmbh Concentrated perfusion medium
EP4196597A2 (en) * 2020-08-14 2023-06-21 Bristol-Myers Squibb Company Manufacturing process for protein
AU2021332355A1 (en) * 2020-08-31 2023-03-23 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
WO2022066595A1 (en) 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
CN114574430A (zh) * 2022-03-22 2022-06-03 成都博宠生物科技有限公司 一种Expi293F细胞培养方法
CN115287251A (zh) * 2022-08-25 2022-11-04 无锡药明生物技术股份有限公司 间歇性灌流联合分批流加培养
US20240076709A1 (en) 2022-09-06 2024-03-07 Amgen Inc. Lean perfusion cell culture methods
IL319172A (en) 2022-09-16 2025-04-01 Amgen Inc Method for collecting products in perfusate cultures
WO2024220354A1 (en) * 2023-04-15 2024-10-24 Puerto Rico Science Technology & Research Trust Methods of producing hiv-1 envelope glycoproteins and guanosine microparticles thereof
WO2025029614A1 (en) 2023-07-28 2025-02-06 Amgen Inc. A method for equilibrating a chromatography medium
CN116790483B (zh) * 2023-08-22 2023-10-20 苏州依科赛生物科技股份有限公司 一种cho细胞无血清培养基及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4499064A (en) 1982-06-03 1985-02-12 Clayton Foundation For Research Assessment of nutritional status of individuals
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
US5045468A (en) * 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5143842A (en) * 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
US7037721B1 (en) * 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
NZ257942A (en) 1992-10-23 1996-04-26 Immunex Corp Preparing a mammalian protein by expression of a fusion protein containing a leucine zipper domain
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
PT1666591E (pt) 1995-06-29 2011-06-01 Immunex Corp Citoquina que induz apoptose
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
EP2243827B2 (en) 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
US20030036505A1 (en) 2000-09-25 2003-02-20 Human Genome Sciences, Inc. Signal transduction pathway component polynucleotides, polypeptides, antibodies and methods based thereon
JP2004532642A (ja) 2001-06-13 2004-10-28 ジェネンテック・インコーポレーテッド 動物細胞の培養方法と動物細胞でのポリペプチド産生
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AU2003220529B2 (en) 2002-03-27 2006-09-07 Immunex Corporation Methods for increasing polypeptide production
ES2456015T3 (es) * 2004-03-05 2014-04-21 Dsm Ip Assets B.V. Procedimiento para cultivar células mediante perfusión continua y flujo tangencial alternante
CN1332024C (zh) * 2004-06-09 2007-08-15 中国科学院大连化学物理研究所 一种海绵细胞的微载体三维培养方法
ATE464918T1 (de) 2004-07-07 2010-05-15 Coloplast As Herstellung von hydrophilen überzügen mit einer 1,3-dioxolan-verbindung
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
JP2008518597A (ja) * 2004-10-29 2008-06-05 セントカー・インコーポレーテツド 化学的規定培地組成物
WO2006128908A1 (en) * 2005-06-03 2006-12-07 Ares Trading S.A. Production of recombinant il-18 binding protein
KR20120009530A (ko) 2006-07-14 2012-01-31 디에스엠 아이피 어셋츠 비.브이. 개선된 세포 배양 방법
US20080206819A1 (en) * 2006-08-21 2008-08-28 Mary Tsao Intensified Perfusion Production Method
WO2008063892A2 (en) 2006-11-08 2008-05-29 Wyeth Rationally designed media for cell culture
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
US20090042253A1 (en) 2007-08-09 2009-02-12 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
BRPI0913475B8 (pt) 2008-09-15 2019-05-07 Genentech Inc vetor
CN101603026B (zh) * 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
EP2459702B1 (en) 2009-07-31 2016-05-04 Baxalta GmbH Cell culture medium for adamts protein expression
KR20180010324A (ko) 2009-08-11 2018-01-30 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
HUE035508T2 (en) 2009-11-17 2018-05-02 Squibb & Sons Llc Methods for enhanced protein production
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
WO2012059857A2 (en) * 2010-11-01 2012-05-10 Symphogen A/S Pan-her antibody composition
US9133493B2 (en) * 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
SG10201702537RA (en) * 2011-07-01 2017-04-27 Amgen Inc Mammalian cell culture
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US11130980B2 (en) 2013-10-31 2021-09-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
JP7311966B2 (ja) * 2015-11-17 2023-07-20 ファイザー・インク 細菌細胞培養物中で多糖を生成するための培地および発酵方法

Also Published As

Publication number Publication date
IL297998A (en) 2023-01-01
US20140255993A1 (en) 2014-09-11
KR101662412B1 (ko) 2016-10-04
CN107988166B (zh) 2022-03-15
IL310968A (en) 2024-04-01
KR102358951B1 (ko) 2022-02-08
KR20200051046A (ko) 2020-05-12
KR20180050433A (ko) 2018-05-14
IL315908A (en) 2024-11-01
CN107988166A (zh) 2018-05-04
AU2012279230B2 (en) 2016-08-18
MX387489B (es) 2025-03-18
AU2012279230A1 (en) 2014-01-09
WO2013006479A2 (en) 2013-01-10
EA201391826A1 (ru) 2014-04-30
US11673941B2 (en) 2023-06-13
CA2838695A1 (en) 2013-01-10
MX351974B (es) 2017-11-06
AU2020281075A1 (en) 2021-01-07
KR101857380B1 (ko) 2018-05-11
LT2837680T (lt) 2020-07-10
HK1197081A1 (en) 2015-01-02
KR102761360B1 (ko) 2025-02-05
US20230129523A1 (en) 2023-04-27
CA2952347A1 (en) 2013-01-10
IL229803B (en) 2020-11-30
KR102108663B1 (ko) 2020-05-07
KR20220021008A (ko) 2022-02-21
AU2020281075B2 (en) 2022-12-22
CY1123146T1 (el) 2021-12-31
EP2726600A2 (en) 2014-05-07
KR20230114317A (ko) 2023-08-01
KR20240005106A (ko) 2024-01-11
ZA201309372B (en) 2014-08-27
WO2013006479A3 (en) 2013-03-28
LT2726600T (lt) 2017-05-25
IL288509B2 (en) 2023-04-01
AU2018203972B2 (en) 2020-09-17
KR102558247B1 (ko) 2023-07-24
US20230117598A1 (en) 2023-04-20
US11292829B2 (en) 2022-04-05
AU2016244255A1 (en) 2016-10-27
US11685772B2 (en) 2023-06-27
CA2838695C (en) 2017-02-14
US20210061888A1 (en) 2021-03-04
IL288509B (en) 2022-12-01
DK2837680T3 (da) 2020-04-27
IL297998B1 (en) 2024-03-01
IL310968B2 (en) 2025-03-01
AU2018203972A1 (en) 2018-06-21
KR20140031375A (ko) 2014-03-12
AU2023201127A1 (en) 2023-03-30
CY1118863T1 (el) 2018-01-10
BR112013033730A2 (pt) 2017-01-31
PT2837680T (pt) 2020-04-17
CN103827292A (zh) 2014-05-28
ES2788132T3 (es) 2020-10-20
JP2014520534A (ja) 2014-08-25
CN103827292B (zh) 2018-01-26
US20200407427A1 (en) 2020-12-31
IL288509A (en) 2022-01-01
ES2625045T3 (es) 2017-07-18
PT2726600T (pt) 2017-04-24
BR122021007265B1 (pt) 2022-02-22
IL278430B (en) 2022-01-01
PL2837680T3 (pl) 2020-08-10
MX2013014937A (es) 2014-04-16
CL2013003792A1 (es) 2014-07-25
EP2837680B1 (en) 2020-02-26
JP5897708B2 (ja) 2016-03-30
US20220185869A1 (en) 2022-06-16
SI2726600T1 (sl) 2017-07-31
US20230227535A1 (en) 2023-07-20
IL310968B1 (en) 2024-11-01
HUE049119T2 (hu) 2020-09-28
CL2016001190A1 (es) 2017-06-09
SG10201702537RA (en) 2017-04-27
SI2837680T1 (sl) 2020-07-31
HK1206057A1 (zh) 2015-12-31
KR20250021605A (ko) 2025-02-13
DK2726600T3 (en) 2017-05-15
US11634476B2 (en) 2023-04-25
EA039023B1 (ru) 2021-11-23
US11827692B2 (en) 2023-11-28
EP2726600B1 (en) 2017-02-15
HUE033279T2 (en) 2017-11-28
KR20160075814A (ko) 2016-06-29
IL297998B2 (en) 2024-07-01
EP2837680A1 (en) 2015-02-18
BR112013033730B1 (pt) 2022-01-25

Similar Documents

Publication Publication Date Title
IL288509A (en) Mammalian cell culture
IL271005A (en) Improved methods of cell culture for adoptive cell therapy
EP2681306A4 (en) CELL CULTURE SYSTEM
IL229879B (en) Culture media for stem cells
EP2759592A4 (en) ADHÄSIONSZELLKULTURVERFAHREN
HUE040455T2 (hu) T-sejt aktiválás inhibitorai
DK2900806T3 (da) Tredimensionel celledyrkning
DK2975115T3 (da) Planteafledt cellekulturmateriale
DK3351620T3 (da) Metabolsk optimeret cellekultur
EP2772530A4 (en) CELL CULTURE ASSAY
GB201110042D0 (en) Growth of cells
DK3144319T3 (da) Cellekultursammensætning indeholdende laminin-521
EP2717924A4 (en) MODULATION OF BETA CELL PROLIFERATION IN THE PANCREATIC GLAND
EP2794841A4 (en) BIOREACTOR
CO6800250A1 (es) Sistema de cultivo de microalgas
BRPI1010684A2 (pt) método para determinar o potencial cardiorregenerativo de células mamíferas
DK2751254T3 (da) Forbedret levedygtighed af probiotiske mikroorganismer under anvendelse af poly-gamma-glutaminsyre
SG11201500386WA (en) Cell culture of corneal endothelial cells
DK2768944T3 (da) Tilsætning af jern til forbedring af cellekultur
BR112013029496A2 (pt) câmara de biorreator
EP2664004A4 (en) PHOTOVOLTAIC CELLS
FR2970496B1 (fr) Structure faisant office de marquise
FI20100378A0 (fi) Viljelymenetelmä
EP2679667A4 (en) Xylose-fermenting microorganism
GB201007855D0 (en) Bioreactor for the culture of cells